Speakers

Expand/Collapse

Adrian Ortiz
Principal Scientist
Amgen

Adrian Ortiz received his B.S. in chemistry from the University of Arizona in 2005 where he performed research under the guidance of Professor Dominic V. McGrath. He then joined the group of Professor K.C. Nicolaou at the Scripps Research Institute in San Diego, CA where he studied the total synthesis of natural products. After completion of his Ph.D. in 2009, he joined the process group of Bristol-Myers Squibb and in 2019 he joined the Pre-Pivotal Drug Substance Team at Amgen in Thousand Oaks, CA where he is currently employed.

Day One

Wednesday May 21 2020

5:30 pm | Development of a Biocatalytic Nitroreductase

Alison Narayan
Assistant Professor
University of Michigan

Alison Narayan's main research interest is identifying enzymes from secondary metabolite pathways with potential synthetic utility and developing methods based on these biocatalysts to enable access to biologically active target molecules. Narayan holds a Ph.D. in organic chemistry from the University of California, Berkeley. She completed her undergraduate studies in chemistry at the University of Michigan, where she later returned as a postdoctoral research fellow in the lab of David Sherman. She started an Assistant Professor in the Department of Chemistry and the Life Sciences Institute at Michigan in 2015. Since this time Alison and her research group have been recognized as a part of C&ENs Talented 12, an Alfred P. Sloan Fellow, a Cottrell Scholar and as the inaugural recipient of the Life Sciences Institute Outreach award.

Day One

Wednesday May 21 2020

3:00 pm | Biocatalysis and Complex Molecule Synthesis

Amin Bornadel
Senior Scientist
Johnson Matthey

Amin Bornadel studied chemical engineering and received a PhD in biotechnology from Lund University in Sweden. For postdoc, Amin went to Germany, where he carried out research within biocatalysis at University of Dresden and Technical University of Hamburg. In 2016, Amin joined Johnson Matthey to work as a biocatalysis researcher. He is currently a senior scientist working in the Biotech team.

Day One

Wednesday May 21 2020

1:00 pm | From Hit to Process: Imine Reductase Catalysed Synthesis of Amines

Christian Lenges
Business Development
DuPont BioMaterials

Christian Lenges, Business Development Leader in the DuPont BioMaterials business, is driving the development, launch & commercialization of emerging, catalytic growth businesses to make industrially important chemicals and materials from renewable feedstocks.  Extended experience in a variety of roles at DuPont with focus on business model innovation, new product line creation and venture leadership in DuPont’s legacy of building an industry leading portfolio of bio-businesses.

Day Two

Thursday May 21 2020

2:00 pm | Enzymatic Polymerization: Engineering Polysaccharides and Material Application Opportunities

David Dodds
Principal
Dodds & Associates

David Dodds has worked in the field of biocatalysis for 40 years.  His experience spans start-up to large pharma/biotech companies, developing processes using single, isolated enzymes to whole cell methods, and most recently synthetic biology and cell-free systems. He was Director of Fermentation and Biocatalysis Development at Bristol-Myers Squibb, prior to which he established the Biotransformations Group at the Schering-Plough Research Institute (now Merck) where his group successfully introduced biocatalysis in over a dozen projects. His early corporate work included developing commercial enzymatic processes for Sepracor. Most recently, David served as interim CTO for Azitra, Inc., a microbiome start-up.  He was previously CTO for Pronghorn Renewables (now Sriya Green Enterprises), a bio-based chemicals start-up targeting products from C5 sugars.  He is a principal at BioChemInsights, which is using a combination of biocatalysis and electrochemistry to improve the carbon efficiency and avoid CO2 generation in biological processes for the production of renewable fuels and bio-based chemicals. David pursued post-doctoral work in molecular biology with Marvin Caruthers at the University of Colorado, Boulder.  He obtained his Ph.D. in synthetic organic chemistry, using biocatalysis, under Bryan Jones at the University of Toronto in 1984.

Day One

Wednesday May 21 2020

9:00 am | Opening Address

Doug Fuerst
Technology Development Leader
GlaxoSmithKline

Doug Fuerst is currently Head of Synthetic Biochemistry at GlaxoSmithKline leading enzyme engineering efforts for biocatalysis.  Doug obtained his PhD in natural product total synthesis from Yale University, followed by postdoctoral research at Harvard University studying asymmetric catalysis.  Doug joined GSK in the Chemical Development department working on the discovery and development of large scale chemical processes with an emphasis on biocatalysis.

Day One

Wednesday May 21 2020

12:00 pm | Development of Novel Enzymatic Catalysed Reactions for Industrial Applications

Jacob Forstater
Senior Scientist
Merck & Co.

Jacob earned his Ph.D. in Physics from UNC-Chapel Hill, where he investigated protein self-assembly and protein-surface interactions. Prior to joining Merck in 2016, Jacob was a postdoctoral fellow at Columbia University, where he developed key nucleotide modifications and algorithms for a nanopore-based next generation sequencing by synthesis technology. Jacob is currently a Senior Scientist in the Enabling Technologies group within Merck’s Small Molecule PR&D department, based in Rahway, NJ. He is responsible for the development of new technologies to enable data rich process development and scale-up of biocatalytic processes.

Day Two

Thursday May 21 2020

10:00 am | Enzyme Immobilization Strategies to Enable Scalable Biocatalytic Cascades

Jacob Grose
Investment Manager
BASF Venture Capital

Jacob E. Grose, Ph.D. is an Investment Manager for BASF Venture Capital, where he heads the Boston office. The portfolio companies he is responsible for include Zapata Computing, NBD Nanotechnologies, and P2 Sciences. Jacob’s role on the team involves sourcing and executing strategic minority investments that bring strategic value to BASF and lead to financially successful exits. Previously, Jacob was a Senior Manager for BASF New Business, where, among other projects, he was involved in the negotiations, due diligence, and subsequent integration for BASF's acquisition of EnerG2 in 2016. Prior to joining BASF in 2012, Jacob was a Senior Analyst at Lux Research, a boutique independent research and advisory firm, providing strategic advice and ongoing intelligence on emerging technologies. Jacob received his Ph.D. in physics from Cornell University and his B.A. in physics from Harvard University. He is the author of nine peer-reviewed scientific articles in the areas of organic electronics and novel superconducting and magnetic materials.

Day One

Wednesday May 21 2020

9:30 am | Fireside Chat: Accelerating the Adoption of Biocatalysis Platforms into Process Chemistry

Jake Janey
Research Fellow
Bristol-Myers Squibb

Jake earned a Ph.D. in organic chemistry from Harvard University in 2003 under the mentorship of Professor David Evans and hig B.S. in chemistry from the University of Chicago under the direction of Professor Viresh Rawal. Jake joined the Process Research group at Merck in 2003 where he contributed to several late-stage projects. In 2007, Jake joined the Merck biocatalysis group, where he worked to combine the use of process chemistry and directed evolution (through a partnership with Codexis) to identify and optimize biocatalysts to broadly impact Merck’s project pipeline. Jake also co-led the team that was responsible for the design, development, and implementation of a new manufacturing route for Januvia using a highly evolved transaminase enzyme. This work was published in Science in 2010 and was recognized not only by awards within Merck, but by the Presidential Green Chemistry Award in that same year. His team also received the 2014 Thomas Alva Edison Patent Award for this project. In 2011, Jake moved to Bristol-Myers Squibb where he heads a Chemical Development Technology Group, which endeavors to discovery and optimize manufacturing routes using robotics, machine learning, HTE crystallization/solubility, chemocatalysis, and biocatalysis. https://www.linkedin.com/in/jake-janey-4aa7613 and Twitter @Phlogiston1

Day Two

Thursday May 21 2020

12:30 pm | Biocatalysis: Past Successes and Future Opportunities to Tame Complexity

Workshop B

1:00 pm | Life Cycle Assessment of Enzyme- Catalyzed Industrial Processes

Jason Micklefield
Professor of Chemical Biology
University of Manchester

Day One

Wednesday May 21 2020

4:30 pm | Discovery, Characterization and Engineering Synthetic Pathways Towards Bioactive Molecules

John Woodley
Professor
Technical University Denmark

Matt Robinson obtained a Master’s degree in Chemical Engineering from the University of Michigan.   He joined Dow AgroSciences in 2012, which subsequently became Corteva Agriscience, as part of the merger and spinout out of Dow Chemical and Dupont.  Matt has held roles in process engineering and as a technical leader in R&D.  In his current role, Matt leads Corteva’s Process Biocatalysis team, as well as fermentation downstream processing and oilseed processing groups.

Day One

Wednesday May 21 2020

11:30 am | Tools for the Translation of Laboratory Biocatalytic Reactions into Industrial Processes

Larry Drumm
President
Biotechnology International Corporation

Day One

Wednesday May 21 2020

6:00 pm | Chair’s Closing Remarks & End of Day One

9:30 am | Fireside Chat: Accelerating the Adoption of Biocatalysis Platforms into Process Chemistry

8:45 am | Chair’s Opening Remarks

Matt Robinson
Technical Leader for Downstream Processing, Biocatalysis & Oilseed Processing
Corteva Agriscience

Matt Robinson obtained a Master’s degree in Chemical Engineering from the University of Michigan.   He joined Dow AgroSciences in 2012, which subsequently became Corteva Agriscience, as part of the merger and spinout out of Dow Chemical and Dupont.  Matt has held roles in process engineering and as a technical leader in R&D.  In his current role, Matt leads Corteva’s Process Biocatalysis team, as well as fermentation downstream processing and oilseed processing groups.

Day Two

Thursday May 21 2020

2:30 pm | Industrializing Biocatalysis for the Crop Protection Industry

Matt Stirling
Senior Scientist
Takeda Pharmaceuticals

Matt Stirling graduated from the University of Glasgow (UK) in 1999 with a bachelor’s degree in chemistry. He joined Cambridge Discovery Chemistry (UK) in 1999 as a medicinal chemist, the company merging with Millennium Pharmaceuticals (UK) in 2000. Transferring across the pond to the medicinal chemistry department of Millennium Pharmaceuticals (USA) in 2003, Matt switched to the process chemistry department in 2005. With the merger of Millennium and Takeda in 2008, the significant expansion of the process chemistry department allowed Matt to contribute to and lead a variety of projects over the past 12 years, from preclinical to late stage development. Matt has a particular interest in biocatalysis and has led efforts to assess and implement biotransformations where applicable, within Takeda’s global API manufacturing processes.

Day Two

Thursday May 21 2020

12:00 pm | Optimization of a Transaminase Process

Niki Patel
Senior Scientist
Merck & Co.

Day One

Wednesday May 21 2020

5:00 pm | The Development of a Biocatalytic Cascade Approach to Islatravir

Day Two

Thursday May 21 2020

3:00 pm | Chair’s Closing Remarks & End of Conference

9:25 am | Chair’s Opening Remarks

Paul Race
Reader in Biological Chemistry
University of Bristol

Dr Paul Race is a Reader in Biological Chemistry in the School of Biochemistry, University of Bristol (UoB). He is a founding Director of the Bristol BioDesign Institute (BBI) and is Bristol lead for the EPSRC funded UK Innovation and Knowledge Centre (IKC) in synthetic biology (SynbiCITE). From 2014-2018 PRR served as Co-Director of the >£14M BBSRC/EPSRC funded Bristol Centre for Synthetic Biology Research (BrisSynBio). He vacated this role in early 2018 to lead the >£2.7M EPSRC funded ‘Manufacturing Immortality’ project, which aims to develop bio-hybrid living materials. His research focuses on the exploitation and manipulation of enzyme complexes, pathways and networks, en route to the development of new bioactive molecules, drug leads and biocatalysts. PRR is co-founder and non-Executive Director of the UoB spinout company Zentraxa Ltd., which uses computational bio-design and high-throughput cellular manufacturing to develop peptide-based biomaterials.

Day One

Wednesday May 21 2020

2:30 pm | Unlocking the Potential of C-C Bond Forming Enzymes by Protein Engineering

Roger Howard
Associate Research Fellow
Pfizer

Roger Howard studied at the University of Manchester, UK and the University of Liverpool, UK, where he completed his PhD studies in biocatalysis and synthetic chemistry under the supervision of Professor Stanley Roberts.  In 2006, Roger joined Pfizer in Sandwich, UK, where he set up a biocatalysis lab supporting late-stage development and later transitioned into a process chemistry role.  In 2017 Roger moved to Pfizer’s Groton, US site to set up a new biocatalysis lab supporting Medicinal Chemistry.  He currently leads Pfizer Medicine Design’s Applied Synthesis Technologies group, which applies biocatalysis as well as flow chemistry, high-throughput experimentation, photochemistry and parallel medicinal chemistry to Pfizer’s early portfolio.

Day Two

Thursday May 21 2020

9:30 am | Application of Biocatalysis Technology to the Unique Challenges of Early Medicinal Chemistry Programs

Ryan M. Phelan
Senior Scientist
AbbVie

My research background is centred on natural product biosynthesis -- using tools ranging from organic chemistry to metabolic engineering to understand and manipulate biosynthetic pathways. My current position at AbbVie is focused on establishing and growing a biocatalyst group at the interface of late discovery and process chemistry. We are very interested in high-throughput experimentation to identify and optimize biocatalytic reactions.

Day One

Wednesday May 21 2020

3:30 pm | Solid, Non-Covalent Formulation of Biocatalysts for Rapid and Accurate Sub-Milligram Dosing to Microtiter Plates and Downstream Applications in High Throughput Screening

Stefan Mix
Head of Biocatalysis
Almac

Stefan Mix was born in Berlin / Germany, where he also completed his secondary education. After graduation with a Diploma in chemistry, he received his doctorate in 2004 from the Technical University of Berlin after working in the group of Prof. Siegfried Blechert on stereoselective synthetic methodology and olefin metathesis. He is the author of several publications, and has been working with Almac Group since 2005. Since starting his career as a bench chemist, he has gained broad industrial experience with particular expertise in the fields of biocatalysis, protein engineering, process development and single enantiomer preparation, and has been responsible for building Almac’s manufacturing network. His hobbies include sailplane gliding, kayaking, gardening and cooking.

Todd K. Hyster
Professor
University of Princeton

A native of the Minneapolis metro area, Todd received his B.S in chemistry from the University of Minnesota – Twin Cities in 2008. He then received his PhD in synthetic organic chemistry from Colorado State University – Fort Collins in 2013 for his work developing methods to prepare nitrogen-containing heterocycles via Rh(III)-catalyzed C–H activation with Tomislav Rovis. As part of these studies, Todd spent months in the lab of Thomas Ward at the University of Basel as a Marie Curie fellow developing an artificial metalloenzyme for C–H activation reactions. Following his doctoral work, he joined the lab of Frances Arnold at California Institute of Technology as an NIH postdoctoral fellow, where his work focused on evolving P450s to catalyze nitrene transfer reactions. Todd started his independent career at Princeton University as an assistant professor in the summer of 2015, where his group’s work is primarily focused on developing strategies to enable substrate promiscuous enzymes to catalyze non-natural free-radical reactions.

Day One

Wednesday May 21 2020

12:30 pm | Photoenzymatic Catalysis – Using Light to Reveal New Enzyme Functions